
Veena Joy, U.S. Lead for Strategic Partnerships, Allergy and Autoimmunity at Thermo Fisher Scientific, discusses the latest in autoimmune disease research and explains why it’s a “good storm,” but not a perfect one.
Veena Joy, U.S. Lead for Strategic Partnerships, Allergy and Autoimmunity at Thermo Fisher Scientific, discusses the latest in autoimmune disease research and explains why it’s a “good storm,” but not a perfect one.
Here’s what you missed this week on Managed Healthcare Executive.
Homecare Homebase revealed over 4 million patients are denied home health services annually, highlighting critical access issues and the impact of proposed Medicare cuts.
Small doses of the involuntary nervous system blocker, atropine, may offer a non-invasive treatment for symptomatic vitreous floaters, according to a recent small study.
The FDA has approved VIZZ, a once-daily, preservative-free eye drop that improves near vision in adults with presbyopia for up to 10 hours.
More than 60 companies pledged to improve healthcare technology during a White House “Make Health Tech Great Again” event hosted as part of the Centers for Medicare & Medicaid Services Health Tech Ecosystem initiative.
New findings reveal Syfovre may protect central vision in macular degeneration patients, delaying vision loss and enhancing treatment strategies.
New findings reveal that early treatment with Syfovre significantly improves vision preservation in geographic atrophy patients, according to Robert Goldberg, M.D., MBA, of the Bay Area Retina Associates.
CVS Health reports Q2 earnings decline due to litigation charges but boost adjusted EPS guidance, highlighting transformation and growth in healthcare services.
Although data breaches in the healthcare industry cost less than they did last year, healthcare is still the most targeted industry for cybercriminals for the fourteenth consecutive year.
Interest in surgical advancements such as retinal detachment repair is driven by the need for balance within the field and a new generation entering the workforce, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.
A session on a surgery technique to treat macular holes using amniotic membrane transplants will be one of the highlights at the 2025 meeting of the American Society of Retina Specialists, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.
There will be a greater focus on surgical topics at the 2025 meeting of the American Society of Retina Specialists, compared with previous years, which reflects the need for balance within the industry, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.
Surveys of American Society of Retina Specialists members have revealed a preference for physicians’ experiences with new therapies, rather than summaries of clinical trial data, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.
Amanda Bogle, a healthcare attorney at Sheppard Mullin, discusses the evolving regulatory landscape for pharmacies, stressing the importance of external legal advice to navigate the complexities of 340B, PBM and Medicaid regulations.
The Joint Commission revamps pediatric care standards, prioritizing children's unique healthcare needs for safer, more effective hospital experiences.
Medicare Advantage enrollment transforms post-acute care, impacting home health, hospice and skilled nursing services amid evolving value-based care challenges.
Here’s what you missed this week on Managed Healthcare Executive.
Rising Medicare exit rates among physicians, especially primary care, highlight growing dissatisfaction and administrative burdens, raising concerns for healthcare access.
Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the importance of preexposure anaphylaxis and why he’s hesitant to jump on the Lenacapavir breakthrough bandwagon.
Proposed Medicaid changes could lead to 1,500 excess deaths and $135 billion in economic losses annually, impacting healthcare and rural communities.
The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
In this interview, Sarah Morris, chief product officer of Audere, explains why they chose to focus on women and young girls and how they have tailored their program to reach them.
Employers increasingly shift health benefit costs to workers in 2026, while prioritizing mental health and innovative affordability strategies.
A scleroderma patient in a Sylvester Comprehensive Cancer Center trial was recently successfully treated with CAR T-cell lymphoma therapy, in what researchers are calling an “immunological reset.”
Audere is closing gaps in HIV care and education with the help of Aimee, their artificial intelligence companion designed to reach women and young girls in South Africa, according to Sarah Morris, CPO of Audere.
Humana has released details about additional, upcoming organizational improvements to encourage a faster prior authorization process, lessen system waste and increase transparency.
This biosimilars market report focuses on rising market complexity and recent activity, including two new approvals and four launches in Q2.